Drugs / Epo-alpha
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00719498 | Nov 2003 → Jul 2004 | cardiac arrest | Janssen Cilag S.A.S. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epo-alpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00719498 ↗ |
| Known as | erythropoietin-alpha | “AIM: To test the possible neuroprotective effect of early high-dose erythropoietin-alpha (Epo-alpha) after out-of-hospital cardiac arrest (OHCA).” PMID 18037223 ↗ Nov 2007 |
| Route | Intravenous | “Intravenous Epo-alpha” NCT00719498 ↗ |